Comparison of Abiraterone Acetate and Docetaxel with Androgen Deprivation Therapy in High-risk and Metastatic Hormone-naïve Prostate Cancer: A Systematic Review and Network Meta-analysis

European Urology

Volumn 73, Issue 6, 2018, Pages 834-844

  Wallis, Christopher J D ^a   Klaassen, Zachary ^a,b   Bhindi, Bimal ^c   Goldberg, Hanan ^a,b   Chandrasekar, Thenappan ^a,b   Farrell, Ann M ^c   Boorjian, Stephen A ^c   Kulkarni, Girish S ^a,b   Karnes, Robert Jeffrey ^c   Satkunasivam, Raj ^a,d  

^a UNIVERSITY OF TORONTO   (Canada)

^b PRINCESS MARGARET HOSPITAL   (Canada)

^c MAYO CLINIC   (United States)

^d HOUSTON METHODIST HOSPITAL   (United States)

Author keywords

Abiraterone; Androgen deprivation therapy; Docetaxel; Hormone na ve; Locally advanced prostate cancer; Metastatic prostate cancer

Indexed keywords

ABIRATERONE ACETATE; DOCETAXEL; PREDNISOLONE; PREDNISONE; ANTIANDROGEN; ANTINEOPLASTIC AGENT;

ADVANCED CANCER; ANDROGEN DEPRIVATION THERAPY; EVENT FREE SURVIVAL; FAILURE FREE SURVIVAL; GLEASON SCORE; HIGH RISK PATIENT; HUMAN; MALE; META ANALYSIS; METASTASIS; NETWORK META-ANALYSIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; REVIEW; SYSTEMATIC REVIEW; COMPARATIVE STUDY; PATHOLOGY; PROSTATE TUMOR; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; SURVIVAL RATE;

ABIRATERONE ACETATE; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DOCETAXEL; HUMANS; MALE; NEOPLASM METASTASIS; NETWORK META-ANALYSIS; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; SURVIVAL RATE;

EID: 85031322705     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2017.10.002     Document Type: Review

References (34)

1. Torre, L.A., Bray, F., Siegel, R.L., Ferlay, J., Lortet-Tieulent, J., Jemal, A., Global cancer statistics. CA Cancer J Clin–2015 65 (2012), 87–108.
2. Weiner, A.B., Matulewicz, R.S., Eggener, S.E., Schaeffer, E.M., Increasing incidence of metastatic prostate cancer in the United States (2004-2013). Prostate Cancer Prostatic Dis 19 (2016), 395–397.
3. Kitagawa, Y., Namiki, M., Prostate-specific antigen-based population screening for prostate cancer: current status in Japan and future perspective in Asia. Asian J Androl 17 (2015), 475–480.
4. Huggins, C.S.R., Hodges, C.V., Studies on prostate cancer: II. The effects of castration on advanced carcinoma of the prostate gland. Arch Surg 43 (1941), 209–223.
5. Hellerstedt, B.A., Pienta, K.J., The current state of hormonal therapy for prostate cancer. CA Cancer J Clin 52 (2002), 154–179.
6. Petrylak, D.P., Tangen, C.M., Hussain, M.H., et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351 (2004), 1513–1520.
7. Tannock, I.F., de Wit, R., Berry, W.R., et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351 (2004), 1502–1512.
8. Barrie, S.E., Potter, G.A., Goddard, P.M., Haynes, B.P., Dowsett, M., Jarman, M., Pharmacology of novel steroidal inhibitors of cytochrome P450(17) alpha (17 alpha-hydroxylase/C17-20 lyase). J Steroid Biochem Mol Biol 50 (1994), 267–273.
9. O'Donnell, A., Judson, I., Dowsett, M., et al. Hormonal impact of the 17alpha-hydroxylase/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer. Br J Cancer 90 (2004), 2317–2325.
10. Ryan, C.J., Smith, M.R., de Bono, J.S., et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 368 (2013), 138–148.
11. Rathkopf, D.E., Smith, M.R., de Bono, J.S., et al. Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302). Eur Urol 66 (2014), 815–825.
12. de Bono, J.S., Logothetis, C.J., Molina, A., et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 364 (2011), 1995–2005.
13. Fizazi, K., Scher, H.I., Molina, A., et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 13 (2012), 983–992.
14. Gravis, G., Boher, J.M., Joly, F., et al. Androgen deprivation therapy (ADT) plus docetaxel versus ADT alone in metastatic non castrate prostate cancer: impact of metastatic burden and long-term survival analysis of the randomized phase 3 GETUG-AFU15 Trial. Eur Urol 70 (2016), 256–262.
15. Sweeney, C.J., Chen, Y.H., Carducci, M., et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med 373 (2015), 737–746.
16. James, N.D., Sydes, M.R., Clarke, N.W., et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet 387 (2016), 1163–1177.
17. James, N.D., de Bono, J.S., Spears, M.R., et al. Abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med 377 (2017), 338–351.
18. Fizazi, K., Tran, N., Fein, L., et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med 377 (2017), 352–360.
19. Bucher, H.C., Guyatt, G.H., Griffith, L.E., Walter, S.D., The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol 50 (1997), 683–691.
20. Wells, G.A., Sultan, S.A., Chen, L., Khan, M., Coyle, D., Indirect evidence: indirect treatment comparisons in meta-analysis. 2009, Canadian Agency for Drugs and Technologies in Health, ON, Canada.
21. Song, F., Altman, D.G., Glenny, A.M., Deeks, J.J., Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses. BMJ, 326, 2003, 472.
22. Tudur, C., Williamson, P.R., Khan, S., Best, L.Y., The value of the aggregate data approach in meta-analysis with time-to-event outcomes. J Royal Stat Soc 164 (2002), 357–370.
23. van Vanlkenhoef, G., Lu, G., de Brock, B., Hillege, H., Ades, A.E., Welton, N.J., Automating network meta-analysis. Res Synth Methods 3 (2012), 285–299.
24. Wallis, C.J.D., Satkunasivam, R., Saskin, R., et al. MP-08.08 Population-based analysis of treatment toxicity among men with castrate-resistant prostate cancer. Can Urol Assoc J, 11, 2017, S250.
25. Ahmed, M., Li, L.C., Adaptation and clonal selection models of castration-resistant prostate cancer: current perspective. Int J Urol 20 (2013), 362–371.
26. Tucci, M., Bertaglia, V., Vignani, F., et al. Addition of docetaxel to androgen deprivation therapy for patients with hormone-sensitive metastatic prostate cancer: a systematic review and meta-analysis. Eur Urol 69 (2016), 563–573.
27. Yamaoka, M., Hara, T., Kusaka, M., Overcoming persistent dependency on androgen signaling after progression to castration-resistant prostate cancer. Clin Cancer Res 16 (2010), 4319–4324.
28. Chandrasekar, T., Yang, J.C., Gao, A.C., Evans, C.P., Targeting molecular resistance in castration-resistant prostate cancer. BMC Med, 13, 2015, 206.
29. Lavaud, P.G.G., Legoupil, C., Joly, F., et al. Efficacy and tolerance of treatments received beyond progression in men with metastatic hormone-naive prostate cancer treated with androgen deprivation therapy (ADT) with or without docetaxel in the GETUC-AFU 15 phase III trial. J Clin Oncol, 34, 2016 abstr 5080.
30. Sydes, M.R., Parmar, M.K.B., James, N.D., et al. Issues in applying multi-arm multi-stage methodology to a clinical trial in prostate cancer: The MRC STAMPEDE trial. Trials, 10, 2009, 39.
31. Stenzl, A., Krivoshik, A., Baron, B., Hirmand, M., Armstrong, A., Efficacy and safety of enzalutamide plus androgen deprivation therapy vs placebo plus androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: the ongoing ARCHES trial. Ann Oncol, 27, 2016.
32. Davis, I.D., Stockier, M.R., Martin, A.J., et al. Randomised phase 3 trial of enzalutamide in first-line androgen deprivation therapy for metastatic prostate cancer: The ANZUP ENZAMET Trial (ANZUP 1304). J Clin Oncol, 34, 2016.
33. Chi, K.N., Chowdhury, S., Radziszewski, P., et al. TITAN: a randomized, double-blind, placebo-controlled, phase 3 trial of apalutamide (ARN-509) plus androgen deprivation therapy (ADT) in metastatic hormone-sensitive prostate cancer (mHSPC). Ann Oncol, 27, 2016.
34. Antonarakis, E.S., Lu, C., Wang, H., et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med 371 (2014), 1028–1038.